ArticleMolecular biology reports2026
The relationship between coronary artery disease and the heat-resistant obscure chaperone Hero11.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeat-resistant obscure (Hero) proteins are a recently described class of intrinsically disordered proteins with chaperone-like activity. C19orf53 (Hero11) suppresses TDP-43 aggregation and is linked to mTORC1 signaling, suggesting a potential role in cellular pathways relevant to coronary artery disease (CAD). We investigated whether C19orf53 genetic variants are associated with CAD risk. METHODS AND
resultsWe genotyped seven C19orf53 single-nucleotide polymorphisms (SNPs) in 2,164 unrelated individuals of Russian ethnicity from Central Russia, including 836 patients with CAD and 1,328 controls. Associations with CAD risk and clinical traits were assessed using regression analyses with permutation correction, followed by functional annotation with bioinformatical resources. SNPs rs11666524 (effect allele [EA] A, OR = 1.21, 95% CI 1.02-1.45, p = 0.04) and rs2277947 (EA A, OR = 1.22, 95% CI 1.01-1.46, p = 0.03) were associated with increased CAD risk in the entire cohort. The strongest effects of C19orf53 SNPs were observed in subgroups without major CAD risk factors for: non-smokers (p = 0.02 for rs10104, rs11666524, and rs2277947); patients with normal fresh fruit/vegetable intake (p = 0.02 for rs10104, and rs346158; p = 0.016 for rs11666524, p = 0.007 for rs2277947, p = 0.04 for rs8107914); and in patients without obesity (p = 0.02 for rs10104, p = 0.01 for rs11666524, p = 0.004 for rs346157, p = 0.01 for rs2277947). Moreover, C19orf53 SNPs contribute to alterations in coagulation parameters.
conclusionsC19orf53 variants are associated with CAD susceptibility and coagulation-related traits, with effects modified by major lifestyle and metabolic risk factors.
Indexed as
Identifiers
42848261What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.